What is the standard of care for locally advanced Melanoma according to NCCN guidelines

Standard of Care for Locally Advanced Melanoma (Stage 3)

Based on the NCCN Guidelines for Patients: Melanoma (2025), locally advanced melanoma—also called stage 3 or regional melanoma—has several well-established treatment approaches depending on whether the cancer can be surgically removed.

Key Treatment Pathways

When Surgery is Possible (Resectable Disease)

According to NCCN Guidelines, the primary treatment options for resectable stage 3 melanoma include:

Surgery-First Approach:

• Complete surgical excision to remove all visible disease with clear margins (the surrounding healthy tissue removed to ensure no cancer cells remain)
• Sentinel lymph node biopsy (SLNB) to check if cancer has spread to nearby lymph nodes
• Complete lymph node dissection (CLND) if sentinel nodes contain cancer

After Surgery - Adjuvant (Follow-up) Therapy:

Once surgery is complete and there's no evidence of remaining disease, NCCN Guidelines recommend these preferred adjuvant immunotherapy options:

• Nivolumab (Opdivo) - a checkpoint inhibitor
• Pembrolizumab (Keytruda) - a checkpoint inhibitor
• Dabrafenib/trametinib - if you have a BRAF V600 mutation (a specific genetic change in the cancer cells)
• Ipilimumab - if you previously received anti-PD-1 therapy

These immunotherapies work by helping your immune system recognize and attack cancer cells.

When Surgery Isn't Possible (Unresectable/Borderline Resectable Disease)

If the melanoma cannot be completely removed surgically, NCCN Guidelines recommend systemic therapy (treatment that travels throughout the body) as the preferred initial approach. This may include:

• Immunotherapy checkpoint inhibitors
• Targeted therapy (if BRAF mutation is present)
• T-VEC (talimogene laherparepvec) - an intralesional therapy that uses a modified virus to kill cancer cells directly in the tumor
• Radiation therapy in selected cases
• Isolated limb infusion/perfusion (ILI/ILP) - a specialized regional chemotherapy procedure for melanoma confined to an arm or leg (only at experienced centers)

Why This Approach?

According to NCCN Guidelines, the combination of surgery plus immunotherapy has become standard because:

1. Surgery removes visible disease - it's the most direct way to eliminate the tumor
2. Adjuvant immunotherapy reduces recurrence risk - it helps prevent the cancer from returning by training your immune system to attack any remaining microscopic cancer cells

Important Questions to Ask Your Oncology Team

Since your specific situation requires personalized evaluation, consider asking:

1. Is my melanoma resectable (can it be surgically removed)? This determines which treatment pathway applies to me.

2. Will I need sentinel lymph node biopsy, and if cancer is found there, complete lymph node dissection?

3. What genetic testing has been done on my tumor? (Specifically, do I have a BRAF mutation? This affects which targeted therapies might be options.)

4. After surgery, which adjuvant therapy do you recommend for me, and why? (Nivolumab, pembrolizumab, dabrafenib/trametinib, or observation?)

5. What are the side effects of the adjuvant therapy you're recommending, and how will we monitor for them?

6. How long will adjuvant treatment last, and what does follow-up care look like?

7. Are there clinical trials available for my specific stage and situation?

Key Takeaway

According to NCCN Guidelines, the standard approach for locally advanced melanoma combines surgery to remove the tumor with adjuvant immunotherapy (or targeted therapy if appropriate) to reduce the risk of recurrence. Your oncologist will determine the best specific approach based on whether your cancer can be surgically removed and the genetic characteristics of your tumor.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.